2016
DOI: 10.5455/ijmsph.2016.16102015178
|View full text |Cite
|
Sign up to set email alerts
|

A comparative evaluation of intravenous labetalol versus oral nifedipine for control of severe pregnancy-induced hypertension with low-dose regimen

Abstract: Background: Hypertensive disorders complicate 5%-10% of all pregnancies and contribute greatly to maternal morbidity and mortality rates. Dangerous hypertension can cause cerebrovascular hemorrhage, hypertensive encephalopathy, and can trigger eclamptic convulsions. Blood pressure (BP) ≥160/110 mmHg in pregnancy requires prompt treatment. Both nifedipine and intravenous (IV) labetalol are effective antihypertensive agents belonging to different pharmacological classes and with different mechanisms of action. T… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 11 publications
1
0
0
Order By: Relevance
“…However, no significant difference was found between the two groups (p=0.09). Our findings of nifedipine being equally effective as labetalol are in keeping with the findings of Raheem et al 8 and Mukherjee at al 9 . In the study by Raheem et al mean time needed to achieve target blood pressure was 46±30 minutes and 54± 42 minutes (p=0.45) in the nifedipine and labetalol group respectively.…”
Section: Mean Time To Achieve Target Blood Pressuresupporting
confidence: 93%
“…However, no significant difference was found between the two groups (p=0.09). Our findings of nifedipine being equally effective as labetalol are in keeping with the findings of Raheem et al 8 and Mukherjee at al 9 . In the study by Raheem et al mean time needed to achieve target blood pressure was 46±30 minutes and 54± 42 minutes (p=0.45) in the nifedipine and labetalol group respectively.…”
Section: Mean Time To Achieve Target Blood Pressuresupporting
confidence: 93%